The FDA released its draft guidance, which provides FDA's interpretation of the terms counterfeit, diverted, fraudulent transactions, and unfit for distribution to aid trading partners in their determination of whether a given product is suspect and/or illegitimate.
Sign-up now to instantly view the document.